Browse FCER2

Summary
SymbolFCER2
NameFc fragment of IgE, low affinity II, receptor for (CD23)
Aliases CLEC4J; CD23; CD23A; FCE2; Fc fragment of IgE, low affinity II, receptor for (CD23A); BLAST-2; IGEBF; C-type ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane; Single-pass type II membrane protein. Cell membrane; Lipid-anchor. Secreted. Note=Also exists as a soluble excreted form, sCD23.
Domain PF00059 Lectin C-type domain
Function

Low-affinity receptor for immunoglobulin E (IgE) and CR2/CD21. Has essential roles in the regulation of IgE production and in the differentiation of B-cells (it is a B-cell-specific antigen).

> Gene Ontology
 
Biological Process GO:0001906 cell killing
GO:0002250 adaptive immune response
GO:0002443 leukocyte mediated immunity
GO:0002449 lymphocyte mediated immunity
GO:0002455 humoral immune response mediated by circulating immunoglobulin
GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002697 regulation of immune effector process
GO:0002699 positive regulation of immune effector process
GO:0002703 regulation of leukocyte mediated immunity
GO:0002705 positive regulation of leukocyte mediated immunity
GO:0002706 regulation of lymphocyte mediated immunity
GO:0002708 positive regulation of lymphocyte mediated immunity
GO:0002712 regulation of B cell mediated immunity
GO:0002714 positive regulation of B cell mediated immunity
GO:0002819 regulation of adaptive immune response
GO:0002821 positive regulation of adaptive immune response
GO:0002822 regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002824 positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002889 regulation of immunoglobulin mediated immune response
GO:0002891 positive regulation of immunoglobulin mediated immune response
GO:0002920 regulation of humoral immune response
GO:0002922 positive regulation of humoral immune response
GO:0002923 regulation of humoral immune response mediated by circulating immunoglobulin
GO:0002925 positive regulation of humoral immune response mediated by circulating immunoglobulin
GO:0006959 humoral immune response
GO:0007219 Notch signaling pathway
GO:0016064 immunoglobulin mediated immune response
GO:0019724 B cell mediated immunity
GO:0031341 regulation of cell killing
GO:0031343 positive regulation of cell killing
GO:0031640 killing of cells of other organism
GO:0032768 regulation of monooxygenase activity
GO:0032770 positive regulation of monooxygenase activity
GO:0035821 modification of morphology or physiology of other organism
GO:0043900 regulation of multi-organism process
GO:0043902 positive regulation of multi-organism process
GO:0044364 disruption of cells of other organism
GO:0050999 regulation of nitric-oxide synthase activity
GO:0051000 positive regulation of nitric-oxide synthase activity
GO:0051341 regulation of oxidoreductase activity
GO:0051353 positive regulation of oxidoreductase activity
GO:0051709 regulation of killing of cells of other organism
GO:0051712 positive regulation of killing of cells of other organism
GO:0051767 nitric-oxide synthase biosynthetic process
GO:0051769 regulation of nitric-oxide synthase biosynthetic process
GO:0051770 positive regulation of nitric-oxide synthase biosynthetic process
Molecular Function GO:0005178 integrin binding
GO:0019863 IgE binding
GO:0019865 immunoglobulin binding
GO:0030246 carbohydrate binding
GO:0050839 cell adhesion molecule binding
Cellular Component GO:0009897 external side of plasma membrane
GO:0098552 side of membrane
> KEGG and Reactome Pathway
 
KEGG hsa04640 Hematopoietic cell lineage
Reactome R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-168256: Immune System
R-HSA-6783783: Interleukin-10 signaling
R-HSA-6785807: Interleukin-4 and 13 signaling
R-HSA-2197563: NOTCH2 intracellular domain regulates transcription
R-HSA-162582: Signal Transduction
R-HSA-449147: Signaling by Interleukins
R-HSA-157118: Signaling by NOTCH
R-HSA-1980145: Signaling by NOTCH2
Summary
SymbolFCER2
NameFc fragment of IgE, low affinity II, receptor for (CD23)
Aliases CLEC4J; CD23; CD23A; FCE2; Fc fragment of IgE, low affinity II, receptor for (CD23A); BLAST-2; IGEBF; C-type ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between FCER2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between FCER2 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
21406718Chronic Lymphocytic LeukemiaPromote immunityMoreover, CLL-derived CD23.CAR(+) T cells released inflammatory cytokines (1445-fold more TNF-β, 20-fold more TNF-α, and 4-fold more IFN-γ). IL-2 was also produced (average release 2681 pg/mL) and sustained the antigen-dependent proliferation of CD23.CAR(+) T cells. Redirected T cells were also effective in vivo in a CLL Rag2(-/-)γ(c)(-/-) xenograft mouse model. These data suggest that CD23.CAR(+) T cells represent a selective immunotherapy for the elimination of CD23(+) leukemic cells in patients with CLL.
Summary
SymbolFCER2
NameFc fragment of IgE, low affinity II, receptor for (CD23)
Aliases CLEC4J; CD23; CD23A; FCE2; Fc fragment of IgE, low affinity II, receptor for (CD23A); BLAST-2; IGEBF; C-type ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of FCER2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolFCER2
NameFc fragment of IgE, low affinity II, receptor for (CD23)
Aliases CLEC4J; CD23; CD23A; FCE2; Fc fragment of IgE, low affinity II, receptor for (CD23A); BLAST-2; IGEBF; C-type ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of FCER2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.5970.335
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)651.5850.111
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.1360.873
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.0660.942
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.5970.218
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.8720.21
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.9880.235
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.7110.161
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.3010.823
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.5250.393
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.3060.685
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0860.799
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of FCER2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 1417011.8-11.80.488
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103033.3-33.30.231
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolFCER2
NameFc fragment of IgE, low affinity II, receptor for (CD23)
Aliases CLEC4J; CD23; CD23A; FCE2; Fc fragment of IgE, low affinity II, receptor for (CD23A); BLAST-2; IGEBF; C-type ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FCER2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolFCER2
NameFc fragment of IgE, low affinity II, receptor for (CD23)
Aliases CLEC4J; CD23; CD23A; FCE2; Fc fragment of IgE, low affinity II, receptor for (CD23A); BLAST-2; IGEBF; C-type ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FCER2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FCER2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolFCER2
NameFc fragment of IgE, low affinity II, receptor for (CD23)
Aliases CLEC4J; CD23; CD23A; FCE2; Fc fragment of IgE, low affinity II, receptor for (CD23A); BLAST-2; IGEBF; C-type ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FCER2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolFCER2
NameFc fragment of IgE, low affinity II, receptor for (CD23)
Aliases CLEC4J; CD23; CD23A; FCE2; Fc fragment of IgE, low affinity II, receptor for (CD23A); BLAST-2; IGEBF; C-type ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of FCER2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolFCER2
NameFc fragment of IgE, low affinity II, receptor for (CD23)
Aliases CLEC4J; CD23; CD23A; FCE2; Fc fragment of IgE, low affinity II, receptor for (CD23A); BLAST-2; IGEBF; C-type ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between FCER2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolFCER2
NameFc fragment of IgE, low affinity II, receptor for (CD23)
Aliases CLEC4J; CD23; CD23A; FCE2; Fc fragment of IgE, low affinity II, receptor for (CD23A); BLAST-2; IGEBF; C-type ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting FCER2 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting FCER2.
ID Name Drug Type Targets #Targets
DB06162LumiliximabBiotechFCER21